PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…

This study tests whether giving a short course of two medicines (hydrocortisone and octreotide) plus using a patch made from the patient's own tissue during surgery can lower the chance of serious complications after a Whipple procedure. The Whipple is a complex operation to remo…

This study looks at whether closely monitoring and controlling blood sugar levels can help people with pancreatic cancer who are receiving chemotherapy. About 50 participants will wear a continuous glucose monitor and be randomly assigned to either tight blood sugar control or st…

This study tests whether adding a new type of targeted nanocell therapy to standard chemotherapy can help people with metastatic pancreatic cancer live longer. The nanocells are designed to deliver a powerful drug directly to cancer cells while also boosting the immune system. Ab…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if t…

This early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS gene mutation. The main goals are to check safety and find the right dose. About 188 people who have tried other tr…

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This early-phase trial tests a new drug called AVA6103 in about 144 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors to kill cancer cells while limiting…

This study is testing a new breath test to find pancreatic cancer earlier. Pancreatic cancer is hard to detect because its symptoms are similar to common illnesses. The test looks for tiny molecules in your breath that cancer cells produce. Researchers will check how accurate the…

This study aims to develop a simple breath test to detect pancreatic cancer earlier. Pancreatic cancer is often found late because early symptoms are vague. The test looks for tiny molecules in breath that may signal cancer. Researchers will collect breath and urine samples from …

This study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…

This study aims to grow mini-tumors (organoids) from small biopsy samples of pancreatic cancer. Researchers will check if these lab-grown organoids match the original tumor's genes and markers. If successful, this could help doctors test treatments on a patient's own tumor cells …